Tumorigenic cells can co-opt normal functions of nonmalignant hematopoietic cells, promoting tumor progression. Recent mouse and human studies indicate that mast cells underpin inflammation in the plexiform neurofibroma microenvironment of neurofibromatosis type 1. In this model, Nf1 homozygous-deficient Schwann cells recruit hyperactive mast cells, promoting tumorigenesis. Here, we discuss the importance of Nf1 gene dosage, delineate hematopoietic contributions to the plexiform neurofibroma microenvironment, and highlight applications to human treatment.
Introduction
Neurofibromatosis type 1 (NF1), also known as von Recklinghausen's disease, is a pandemic genetic disorder affecting approximately one in 3000-3500 persons worldwide [1, 2] . NF1 results from autosomal dominant mutations in the NF1 tumor suppressor gene, which encodes neurofibromin, a p21 ras (Ras) guanosine triphosphatase (GTP) activating protein (GAP) [3,4 ,5 ] . Among other nonmalignant manifestations, individuals with NF1 frequently develop cutaneous, subcutaneous, or plexiform neurofibromas, comprised of irregular Schwann cells, fibroblasts, and mast cells [6, 7 ] . Although individuals with NF1 are born with one mutated NF1 allele in all cells (i.e. germ-line mutation), loss of the residual normal NF1 allele (i.e. loss of heterozygosity or LOH) in tissues such as Schwann cells precedes tumor formation, consistent with NF1's categorization as a tumor suppressor gene [7 ] . Similarly, in a mouse model mimicking the human condition, plexiform neurofibroma development requires Nf1 À/À Schwann cells [8] , analogous to NF1 LOH in humans. Although biallelic gene loss precedes neurofibroma formation in both humans and mice, mouse models have additionally demonstrated that tumor formation requires Nf1 haploinsufficiency (Nf1 þ/À ) of cellular components within the tumor microenvironment [8, 9] . Recently, bone marrow transplantation experiments have shown that tumor formation specifically requires the inflammatory contributions of Nf1 þ/À and c-kit-dependent bone marrow and, arguably, hyperactive mast cells [10 ] . Here, we discuss gene dosage in NF1 pathogeneses, argue that interactions between tumorigenic Schwann cells, deregulated mast cells, and the microenvironment critically underpin plexiform neurofibroma formation, and show how these findings have led to the successful medical treatment of a patient with a debilitating plexiform neurofibroma.
Nf1 gene dose modulates neurofibromatosis type 1 pathogeneses
In humans and in mice, NF1 manifestations result from a combination of ubiquitous NF1/Nf1 heterozygosity and unpredictable NF1/Nf1 LOH in different cell lineages. These genetic doses dictate both generalized and variable localized maladies. For example, LOH in Schwann cells precedes plexiform neurofibroma formation, whereas LOH in chromaffin cells induces pheochromocytoma, two disparate yet frequently encountered NF1 symptoms (Table 1 [ 10 ,11,12 ,13 ,14,15,16 -19 ] ). Moreover, regions of particular tissues may rely more heavily on neurofibromin than other unaffected regions. For example, astrocytes of the optic nerve, brain stem, and cerebellum express more NF1 and hyperactively proliferate in its absence when compared with astrocytes from the neocortex, suggesting why gliomas in NF1 patients arise more frequently in these locations [20 ] .
Despite the persistent requirement for Nf1 LOH in tumor cells of origin, Nf1 haploinsufficiency also alters cell fate and function. These phenomena have been reported in mast cells and melanocytes [21, 22] , neurons [17 ], nondysplastic astrocytes [23] , osteoblasts and osteoclasts [18 , 24, 25] , endothelial cells [19 ,26] , smooth muscle cells [27] , keratinocytes [28] , and fibroblasts [29] . Nf1 haploinsufficient cells typically demonstrate gain-in-functions secondary to deregulated Ras signaling. Although aberrancies in these lineages may underpin generalized NF1 symptoms such as skeletal dysplasia, learning deficiencies, and vascular disorders, a mouse model of plexiform neurofibroma formation demonstrates that localized tumorigenesis depends on Nf1 haploinsufficiency in supporting tissue.
Plexiform neurofibroma formation requires Nf1 haploinsufficiency
Concordant with these data showing Nf1 gene dosage effects in multiple cell lineages, a plexiform neurofi-broma mouse model depends on not only a population of Nf1 À/À Schwann cells but also an Nf1 haploinsufficient cellular background [8, 9] . Nf1 homozygous deficiency is embryonically lethal due to heart malformations, and Nf1 À/À chimeric mice but not Nf1 þ/À mice develop neurofibromas [30] [31] [32] . In light of these data, Zhu et al. [8, 33] created a Schwann cell-specific Nf1 conditional knockout on an Nf1 haploinsufficient background. In this mouse, loxP sites, the 34-bp recognition sequence for the Cre recombinase enzyme, flank Nf1's exon 31 and 32 on one allele (e.g. Nf1 flox/ ), and the other allele carries a traditional 'knockout' Nf1 mutation (thus, Nf1 flox/À ). This circumvents the problem of embryonic lethality while allowing tissue-specific, Cre-directed exon deletion and genetic level inhibition. In the plexiform neurofibroma tumor model, the mouse carries the Cre recombinase transgene under control of the Krox20 gene promoter element (Nf1 flox/À ;Krox20cre), which expresses Cre recombinase with specificity in 10-20% of Schwann cells [8, 33] . Although mice with Nf1 À/À Schwann cells but wild-type cellular backgrounds (Nf1 flox/flox ;Krox20cre) never develop neurofibromas, mice with additionally heterozygous backgrounds (Nf1 flox/À ;Krox20cre) reliably form dorsal root ganglia tumors comprised of irregular Schwann cells, fibroblasts, and mast cells. These findings grossly and histologically mimic plexiform neurofibromas found in individuals with NF1.
With the insights of the Nf1 flox/À ;Krox20cre model, the question arises as to which haploinsufficient cells or cellular interactions, or both, underlie neurofibroma genesis. The Nf1 þ/À mast cell seems a likely candidate: mast cells infiltrate neurofibroma tissue in large numbers, neurofibroma tissue and Schwannoma-derived Schwann cells express high levels of stem cell factor (SCF) mRNA [34, 35] , SCF/c-kit signaling critically regulates mast cell hematopoiesis and physiology [36] , and, generally, mast cells and other inflammatory cells have been increasingly implicated in neoplasia [37] [38] [39] . Likewise, mast cells can synthesize and secrete matrix metalloproteinases; proinflammatory cytokines such as interleukin 6, tumor necrosis factor-alpha, and chemokine (C-C motif) ligands 2-4; and mitogens such as nerve growth factor, vascular endothelial growth factor (VEGF), and plateletderived growth factor (PDGF). These secreted factors modulate the differentiation and growth of multiple cell types, effect extracellular matrix remodeling, and induce collagen deposition, angiogenesis, and generalized inflammation [40, 41] .
Moreover, studies of Nf1 haploinsufficient mast cells and melanocytes provided initial evidence that haploinsufficiency of a tumor suppressor gene can substantially regulate lineage-specific cell fate and function [21] . Ingram et al. [21] found that an intercrossed Nf1 þ/À genotype corrects multiple deficiencies of the W 41 /W 41 mouse, a mutation compromising c-kit receptor tyrosine kinase activity by approximately 85%. This mutation ablates mast cell cytogenesis and produces a predominantly white coat due to melanocyte dysfunction [42] . However, Nf1 þ/À ;W 41 /W 41 mice show partially restored dermal mast cell numbers, elevated bone marrow-derived mast cell colonies, increased SCF-induced proliferation and survival, and biochemical hyperactivity in c-kit signaling pathways.
Plexiform neurofibroma formation requires Nf1 R/S and c-kit R marrow
In accordance with the above observations, recent transplantation experiments have indicated that Nf1 haploinsufficient and c-kit-dependent bone marrow is required for plexiform neurofibroma formation [10 ] . First, Nf1 þ/À marrow transplanted into lethally irradiated Nf1 flox/flox ; Krox20cre mice (which do not develop tumors) induces tumor formation similar to the tumorigenic Nf1 flox/À ; Krox20cre mouse model. Second, transplantation of wild-type bone marrow into the Nf1 flox/À ;Krox20cre mouse abolishes tumor formation in the normally reliable tumor model. In the first experiment, the mouse carries Nf1 À/À Schwann cells; Nf1 þ/À marrow; and wild-type fibroblasts, vascular cells, neurons, and so on. In the second experiment, the mouse carries Nf1 À/À Schwann cells; wild-type marrow; and Nf1 þ/À fibroblasts, vascular cells, neurons, and so on. Therefore, we can conclude that Nf1 þ/À bone marrow, combined with Nf1 À/À Schwann cells, is required and sufficient for plexiform neurofibroma formation [10 ].
Furthermore, genetic inhibition of c-kit (i.e. W mutations), the principal molecular effector of mast cell development, protects against the tumorigenic potential of Nf1 þ/À marrow. Marrow derived from Nf1 þ/À mice intercrossed with W 41 or W sh mice and transplanted into Nf1 flox/flox ;Krox20cre mice does not induce tumor formation as in Nf1 flox/flox ;Krox20cre mice reconstituted with Nf1 þ/À marrow. Thus, we can additionally conclude that plexiform neurofibroma formation in a mouse model requires Schwann cell Nf1 deficiency, marrow Nf1 haploinsufficiency, and marrow expressing high-functioning c-kit receptors. Given these direct data and other inferences, the Nf1 þ/À mast cell arises as the premier culprit promoting the plexiform neurofibroma microenvironment [10 ] .
Other recent studies have additionally sought to pinpoint the developmental stage at which Nf1 À/À Schwann cells, glial progenitors, or both, become tumorigenic. Although Nf1 À/À neural crest stem cells do not induce tumors when transplanted into the peripheral nerves of Nf1 þ/À mice [43 ] , tumors do arise in mice with Nf1 À/À nonmyelinating Schwann cells (i.e. Remak bundles) on an Nf1 þ/À background (Nf1 flox/À ;P0-Cre) [44 ] , deepening the observations from the Krox20-Cre plexiform neurofibroma model. Alternately, widespread and early (E12.5) biallelic loss of Nf1 in glia (Nf1 flox/flox ;Dhh-Cre) permits dermal and plexiform neurofibroma formation despite a wild-type cellular background [13 ] . Thus, developmental timing of Nf1 genetic loss critically influences tumor formation. Although Cre promoters controlling Nf1 genetic loss in a limited subset of Schwann cells [e.g. Krox20-Cre, P0-Cre, and Periostin-Cre (unpublished)] underlie the models closely recapitulating tumor formation of genetic NF1, the widespread and early glial loss induced by Dhh-Cre provides an apt model for spontaneous, congenital neurofibroma formation. Tellingly, mast cells infiltrate tumor tissue in all of the aforementioned models.
Nf1 R/S mast cells and the microenvironment hypothesis
Several in-vitro and in-vivo studies have suggested mechanisms through which the Nf1 þ/À mast cell influences the plexiform neurofibroma microenvironment. In the current hypothesis, Nf1 À/À Schwann cells co-opt and activate Nf1 þ/À mast cells through secreted SCF, causing mast cells to differentiate, proliferate, degranulate, and synthesize/secrete cytokines. These activities, in turn, induce continued Schwann cell expansion, aberrant fibroblast bioactivity, the in-growth of new vasculature, and the perpetuation of marrow-based inflammation (Fig. 1) . As evidence, Nf1 À/À Schwann cells release pathological concentrations of SCF under normal culture conditions, and this SCF provides a chemotactic and activating signal most potently for Nf1 þ/À mast cells [45] . Nf1 À/À Schwann cell-conditioned media drives Nf1 þ/À mast cell chemotaxis at approximately twice the rate of wild-type mast cells, an effect duplicated with recombinant SCF and ablated with genetic and pharmacologic disruption of c-kit. In turn, activated Nf1 þ/À mast cells secrete high levels of transforming growth factor-beta, inducing Nf1 þ/À and wild-type fibroblasts to migrate, proliferate, and synthesize collagen, a protein comprising nearly half the dry weight of the tumor [29, 46] . Likewise, mast cells potentiate Schwann cell-axonal disassociation in peripheral nerve injury and neuronal tumor models [47] . As described above, SCF-activated mast cells produce a host of inflammatory and mitogenic factors with potential yet relatively unexplored roles in the plexiform neurofibroma microenvironment.
Biochemically, Nf1 and SCF-dependent mast cell pathophysiology results from deregulated Ras signaling. Multiple ligand-receptor interactions, including SCF binding at the c-kit receptor tyrosine kinase, induce Ras to its GTP-bound state. Ras-GTP initiates multiple downstream signaling networks [48, 49] . Ras-GTP is converted to its inactive guanine diphosphate-bound state by neurofibromin, a highly conserved GAP encoded by 350 kb of genomic DNA on human chromosome 17q11.2 (chromosome 11 in mice) [50] [51] [52] [53] . In SCFstimulated mast cells, Nf1 haploinsufficiency increases Ras-GTP activity and potentiates the phosphorylation and activity of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI-3K) pathways, which involve activated p44/p42 [extracellular regulated kinase (ERK) 1/2], p38, Akt, and RacGTPases [21, 54, 55] . Genetic and chemical inhibition of MEK, PI-3K, and p38 suggest a primarily proliferative role for the Ras-Raf-MEK-ERK cascade and a primarily chemotactic role for the PI-3K-Rac-Pak-p38 cascade [21, [55] [56] [57] . Hypothetically, ERK nuclear translocation and activity regulate the G1-to-S transition, whereas p38 regulates cytoskeletal rearrangement and motility [55, 58, 59] . However, these pathways directly crosstalk through the p21activated kinases (Paks), which phosphorylate Raf and MEK, further potentiating ERK activity [55] . Additionally, PI-3K-Rac2 activates Akt, which increases mast cell survival through antiapoptotic pathways [57] . These data mechanistically validate Nf1 þ/À mast cell gain-infunction, and they demonstrate putative, specific targets for NF1 disease management.
Translation to the clinical treatment of human plexiform neurofibromas
In light of the data implicating the Nf1 þ/À mast cells in tumor formation and their dependence on hyperactive c-kit pathways, pharmacological c-kit inhibition should modulate disease course. Concordantly, imatinib mesylate (Gleevec; Novartis International AG, Basel, Switzerland), a potent inhibitor of c-kit, PDGFb, and the bcr/abl receptor tyrosine kinases [60 ] , successfully reduces existing plexiform neurofibroma volume and de-novo genesis in the Nf1 flox/À ;Krox20cre mouse model [10 ] . Although imatinib inhibits c-kit-dependent mast cell activity, the drug may also contribute through simultaneous inhibition of PDGF receptor and c-abl, signaling molecules involved in Nf1-dependent angiogenesis [27] and fibroblast activity, respectively [29] .
From the results of drug treatment in the mouse model, clinicians have used imatinib to treat a 3-year-old with NF1. This patient presented with hallmarks of NF1 at the age of 6 months and developed a progressive, nonresectable, and debilitating plexiform neurofibroma encasing her carotid artery and jugular vein. After 3 months of treatment with 350 mg/m 2 per dose of imatinib mesylate, the tumor decreased in volume by 70%. Sleeplessness, fatigue, and drooling associated with airway compression resolved, and the patient remains stable and relatively healthy without further imatinib treatment [10 ] . Now, a phase II clinical trial of imatinib In this model, the Nf1 À/À Schwann cell secretes pathological concentrations of SCF, the ligand for the c-kit receptor tyrosine kinase on the Nf1 þ/À mast cell. C-kit dimerization activates Ras-Raf-MEK-ERK and PI-3K-Rac-Pak-p38 signaling pathways, which promote mast cell proliferation, survival, migration, and cytokine synthesis/secretion. These pathways crosstalk through Pak phosphorylation of Raf and MEK and are negatively regulated through NF1 GAP activity. Secreted products such as VEGF, TGFb, NGF, and MMPs promote tumor vascularization, collagen deposition, Schwann cell expansion, and extracellular matrix remodeling, respectively. These products initiate and promote tumor growth. ERK, extracellular regulated kinase; FGF, fibroblast growth factor; GAP, GTPase-activating protein; MMPs, matrix metalloproteinases; NGF, nerve growth factor; PI-3K, phosphoinositide 3-kinase; SCF, stem cell factor; TGF-b, transforming growth factor-beta; VEGF, vascular endothelial growth factor.
in plexiform neurofibroma management is in its final stages.
Conclusion
As observed in the mast cell and other cell types, Nf1 gene dose modulates cell fate and physiology. Although some NF1 disorders -such as myeloid leukemia [14, [61] [62] [63] [64] and early developmental glial tumors [13 ] -require Nf1 LOH in only the tumor cell of origin, Nf1 haploinsufficiency in mast cells critically underpins the inflammatory microenvironment of the plexiform neurofibroma. These data directly compare with mouse models of at least two other NF1 conditions. Firstly, Nf1-dependent optic glioma formation requires Nf1 deficiency in astrocytes and Nf1 haploinsufficiency in surrounding brain tissue, most likely the microglia [11, 65] . Secondly, dermal neurofibroma formation requires Nf1 deficiency in skin-derived precursor cells and haploinsufficiency in the surrounding dermal tissue [12 ] . Despite these data from murine models, we recognize that, in humans, variable and, as yet, largely undefined modulators independent of the NF1 locus can contribute to heterogeneous disease manifestations and may explain family-linked predispositions to certain symptoms [66 ] .
Many questions concerning the plexiform neurofibroma microenvironment persist. The cellular actors downstream of mast cell hyperactivity need further exploration, and specific molecules modulating Nf1-dependent tumor development continue to emerge. For example, recent research indicates that phosphatase and tensin homolog (PTEN) protects against neurofibroma development and its transformation to malignancy [67 ]. Likewise, microarray and RNA data indicate that dermal and plexiform neurofibromas aberrantly express Sox9, a transcription factor normally expressed in maturing -but not fully differentiated -Schwann cells [68 ] . Moreover, data from the study of gliomagenesis have revealed that enhanced NF1 proteosomal degradation -and not exclusively genetic loss -can instigate tumor genesis [69 ] . Thus, novel mechanistic discoveries remain to be made across the breadth of NF1 disease. Much like the cellular and molecular discoveries showing the critical contribution of the mast cell to the plexiform neurofibroma, further discovery of Nf1-dependent cells and molecules will impel effective medical therapies targeted at novel pathogenic effectors.
